MedPath

Molecular Partners and Orano Med Expand Partnership for Cancer Therapy Development

Molecular Partners and Orano Med have announced an expanded partnership to develop Targeted Alpha Radio-Therapies for cancer, aiming to enter a first-in-human study for Radio-DARPin MP0712 against DLL3 by 2025 and co-develop a program targeting Mesothelin.

Molecular Partners has outlined its clinical expansion plans and strengthened its strategic focus on radiopharma for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference. A significant part of this plan includes the Radio-DARPin MP0712 against DLL3, developed in collaboration with Orano Med, which is set to enter its first-in-human study in 2025. Additionally, Mesothelin has been named as the second target in the Radio-DARPin pipeline, with a program to be co-developed with Orano Med.
The expanded partnership between Molecular Partners and Orano Med is aimed at fueling a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, increasing the total number of programs up to ten. This collaboration highlights the commitment of both companies to advancing cancer therapy through targeted alpha radio-therapies, leveraging their combined expertise and resources to bring innovative treatments to patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Molecular Partners' Radio-DARPin MP0712 Enters Clinical Trials for DLL3-Expressing Tumors

Molecular Partners' Radio-DARPin MP0712, targeting DLL3, is set to begin first-in-human trials in 2025, marking a key advancement in targeted cancer therapy.
The collaboration between Molecular Partners and Orano Med expands to ten Radio-DARPin programs, enhancing their pipeline of targeted alpha therapies.

Metsera's GLP-1 Therapy Shows Promise in Phase II Trial Amidst M&A Speculation

Metsera reported promising Phase II data for its investigational subcutaneous GLP-1 therapy, positioning it as a potential acquisition target.
The GLP-1 space is expanding into new indications like heart disease, sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH).

INOVIQ's Exosome Therapy Shows Promise in Triple-Negative Breast Cancer

INOVIQ reports a breakthrough in breast cancer therapy using genetically engineered natural killer cell-derived exosomes to deliver cancer-killing agents directly to triple-negative breast cancer cells.
The experimental therapy demonstrated the ability to kill over 30% of targeted triple-negative breast cancer cells at the highest dose in a proof-of-concept study.

Faron Pharmaceuticals' Bexmarilimab Shows Promise in Myelodysplastic Syndrome Treatment

Faron Pharmaceuticals' BEXMAB trial shows a 79% overall response rate in relapsed/refractory myelodysplastic syndrome (r/r MDS) patients treated with bexmarilimab and azacitidine.
The median overall survival (mOS) in r/r MDS patients remains at 13.4 months, significantly longer than the 5-6 months typically expected with standard care.

CRUK Receives $225 Million Investment; New CAR-T Cell Facility; Promising Gene Therapy for Parkinson's

Cancer Research UK (CRUK) has received a US$225 million investment to enhance cancer research and treatment, focusing on personalized medicine and early detection.
The University of Cambridge is opening a new facility to manufacture CAR-T cell therapies, expanding treatment options for patients across the East of England.

Pfizer Invests in Molecular Glue Research; Jazz's Zepzelca Shows Promise in Lung Cancer

Pfizer has invested $49 million in Triana Biomedicines to discover novel molecular glue degraders for oncology, with Pfizer holding an exclusive option to license promising candidates.
Jazz Pharmaceuticals' Zepzelca, combined with Roche's Tecentriq, demonstrated improved overall survival and progression-free survival in small cell lung cancer patients in the IMforte Phase 3 study.

Roche's Subcutaneous Tecentriq Approved; Gilead's HIV Shot Shows Promise

The FDA approved Roche's Tecentriq Hybreza, the first checkpoint inhibitor available as a subcutaneous injection, offering a faster administration time of about seven minutes.
Gilead's twice-yearly lenacapavir HIV shot reduced infection risk by 96% in a Phase 3 trial, leading to halted trial and plans for regulatory filings and a potential 2025 launch.

Bicara Therapeutics and Zenas BioPharma Aim for $200 Million IPOs

Bicara Therapeutics plans a $200 million IPO to advance ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β for solid tumors.
Zenas BioPharma also seeks $200 million through an IPO to support obexelimab, a CD19 and FcγRIIb targeting antibody in Phase 3 for IgG4-RD.

Advancements in Neuroplastogens, KRAS G12C Inhibitors, and Other Therapies Highlighted by Recent Deals and Clinical Readouts

Significant financial transactions in May 2024 advanced the development of next-generation neuroplastogens and KRAS G12C inhibitors, signaling strong investment in these areas.
Positive clinical readouts were reported for tetrameric transthyretin (TTR) stabilizers, showing promise in treating related conditions.

Merck and N-Power Medicine Collaborate to Expand Oncology Clinical Trial Access

Merck and N-Power Medicine are collaborating to broaden oncologist and patient participation in oncology clinical research, utilizing N-Power's real-time registry and AI-driven platform.
The collaboration aims to implement multiple trials within the N-Power Medicine Network, extending the clinical development model to other oncology indications and cancer centers.

Reference News

[1]
Want to stay updated on the latest news?
globenewswire.com · Jan 12, 2025

Molecular Partners plans clinical expansion and strengthens radiopharma focus, with MP0712 entering human trials in 2025...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy